Kedudukan dalam Saham
#38911
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Perubahan (1 hari)
-3.69%
Perubahan (1 tahun)
-95.30%
Perdagangan Valion Bio, Inc. (VBIO)
Harga VBIO dengan permodalan pasaran b
Modal pasaran bagi Valion Bio, Inc.(VBIO)
Modal Pasaran: $681.26K
Sehingga August 2026, Valion Bio, Inc. mempunyai modal pasaran sebanyak $681.26K. Ini menjadikan Valion Bio, Inc. syarikat ke-38911th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Valion Bio, Inc. dari 2021 hingga 2026
VBIO berbanding dengan 5 teratas yang paling popular stocks
| Harga VBIO |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.470T
|
+802,852,590.36%
|
|
|
|
|
$4.467T
|
+655,704,326.80%
|
|
|
|
|
$4.174T
|
+612,742,230.51%
|
|
|
|
|
$3.700T
|
+543,120,204.32%
|
|
|
|
|
$2.854T
|
+418,978,030.97%
|
